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OBJECTIVE: To compare the efficacy and tolerability of a fixed combination of 0.3% gatifloxacin and 1%
prednisolone (ZypredH) versus the individual components used separately (ZypredH and PredfortH) for infection
prophylaxis and inflammation control after cataract surgery with intraocular lens implantation.
METHODS: A prospective, randomized, double-blind, parallel-group study of 108 patients who underwent
phacoemulsification and intraocular lens implantation was conducted. After random assignment, 47 eyes
received the fixed combination of topical 0.3% gatifloxacin/1% prednisolone drops, and 61 eyes received the
same doses of the individual components as separate solutions four times a day for 15 days. Baseline and
postoperative assessments were made on postoperative days 1, 7, 15, and 20.
RESULTS: All objective (best corrected visual acuity, sign of active ocular inflammation, central and incisional
corneal edema, the number of cells per high-power field in the anterior chamber, and intraocular pressure) and
subjective (eye pain, photophobia, burning sensation, itching, and foreign body sensation) criteria of efficacy
were similar in both groups, with no significant differences. Group I included 47 eyes that received the fixed
combination of gatifloxacin/prednisolone acetate eye drops and a placebo eye drop solution. Group II included
61 eyes that were treated with 0.3% gatifloxacin and 1% prednisolone acetate eye drops separately. The
intraocular pressure was slightly higher in Group II (p,0.05).
CONCLUSION: Treatment with the fixed-dose combination of gatifloxacin/prednisolone eye drops was as
effective as the non-fixed combination in preventing infection and controlling inflammation after
phacoemulsification and intraocular lens implantation.
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& INTRODUCTION
The aging population together with technological
advancements in ophthalmic surgery, particularly in
cataract surgery, have increased the number of phacoemul-
sifications around the world (1,2)
Acute endophthalmitis is the most important complication
after cataract surgery; the incidence of endophthalmitis
among cataract patients ranges from 0.04% to 0.099% in the
developed world (3,4). The outcome of this intraocular
infection can be devastating to the patient and result in
significant loss of vision and even loss of the eye (5). Therefore,
prophylaxis with antibiotics and anti-inflammatory agents is
mandatory in the cataract surgery postoperative period.
The fourth-generation fluoroquinolone eye drops (gati-
floxacin and moxifloxacin) are the most commonly used
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drugs for prophylaxis against endophthalmitis in cataract
surgery. These eye drops increase the spectrum of antibiotic
coverage, including resistant strains, and present a lower
risk for antibiotic resistance (5-7).
Topical corticosteroids are commonly used as a routine
treatment over several weeks to reduce the inflammatory
reaction after cataract surgery (8). Corticosteroids are
successful at reducing ocular inflammation because of their
ability to inhibit nearly all chemical mediators in the
inflammatory cascade. They downregulate inflammation
by inhibiting deoxyribonucleic acid (DNA) transcription in
the cell nucleus and interrupt the inflammatory cascade
by increasing histaminase production; histaminase is an
enzyme that breaks down unbound histamine into an
inactive metabolite by inhibiting the production of phos-
pholipase A2, which produces arachidonic acid from
phospholipids in cell walls. Arachidonic acid is the main
precursor to inflammatory mediators, such as prostaglan-
dins and leukotrienes (9). Prednisolone acetate 1% has been
used for inflammation control in cataract surgery, an
important factor in the healing process (10,11). This
corticosteroid achieves its highest aqueous level (669.9 ng/
ml) within 120 min and maintains a significant level over
24 h; thus, a twice-daily application of prednisolone acetate
1% may be suitable for uncomplicated postoperative
cataract cases (12).
Antibiotic and anti-inflammatory eye drops are necessary
for cataract surgery postoperative management; combined
doses with both drugs were developed to reduce the
number of applications required and the potential toxic
effects due to preservatives (13). Even at low concentrations,
the preservatives and buffering agents cause some degree of
cell damage to ocular tissue as evaluated using corneal and
conjunctival cells in tissue culture. The toxicity increases
with increasing drug concentrations. Corneal toxicity
caused by preservatives may cause ocular discomfort and
changes in vision and may interfere with patient compliance
with the recommended dosage (14).
The aim of this study was to compare the inflammation
control and infection prophylaxis after cataract surgery
provided by a fixed combination of gatifloxacin 0.3% and
prednisolone acetate 1% (ZypredH, AllerganH) versus the
individual components (ZypredH and PredfortH).
& METHODS
Phacoemulsification and IOL implantation was per-
formed in 129 patients with cataract. Each patient had
surgery in only one eye. Exclusion criteria included history
of uveitis or chronic ocular inflammation, pseudoexfoliation
syndrome, history of ocular trauma, uncontrolled diabetes,
pregnant and nursing women, allergy or sensitivity to any
component of the medications, serious systemic diseases
and perioperative complications, such as anterior capsule
rupture and vitreous loss. Patients were randomly assigned
using the Research Randomizer software (site: www.
randomizer.org); the value 1 was assigned to patients
enrolled in Group I, and the value 2 was assigned to
patients enrolled in Group II; 64 patients were allocated to
Group I, and 65 patients were allocated to Group II.
The group assignment was masked from all patients and
investigators. Each patient was given two identical bottles
labeled according to their group assignment. All bottles
were opaque and patients were instructed to apply one drop
from each bottle in the operated eye every 6 h with a 5-min
interval between drops, beginning one day prior to the
surgery until the 15th day.
All patients underwent monocular cataract removal by
phacoemulsification and IOL implantation performed by
two experienced surgeons (AA and AAB) using the phaco
chop technique under topical anesthesia.
At the screening visit, patients who met the eligibility
criteria were informed of the requirements of the study and
the risks involved before being asked to sign an informed
consent form.
Patients were examined on postoperative days 1, 7, 15,
and 20. Best corrected visual acuity (BCVA) was measured
with an Early Treatment Diabetic Retinopathy Study
(ETDRS) chart and presented in logMAR values. Patients
were asked to subjectively rank their eye pain on a five-
point scale from 0 (none) to 5 (severe). They were also asked
about photophobia, burning sensation, itching, and foreign
body sensation. Any sign of active ocular inflammation
(redness, edema, tearing, or discharge) was documented.
Conjunctival hyperemia and central and incisional corneal
edema were evaluated by slit-lamp examination and
classified from 0 (no edema) to 4+.
Using the narrowest slit of the slit lamp (0.5-mm wide, 8-
mm high), the number of cells per high-power field in the
anterior chamber was counted and recorded on a scale
where 0 represented #5 cells, 1 represented 5 to 10 cells, 2
represented 11 to 20 cells, 3 represented 21 to 50 cells, and 4
represented $50 cells. A Goldmann applanation tonometer
was used to measure the intraocular pressure on post-
operative days 7, 15, and 20. The presence of hypopyon,
posterior capsule opacity, and pigments or membrane in
front of the IOL were also assessed. At each visit, patients
were also questioned regarding treatment compliance and
occurrence of any adverse event since the previous
examination. On postoperative day 15, patients were
instructed to discontinue the medications.
The data for the patients who met the inclusion/exclusion
criteria underwent statistical analysis with Fisher’s Least
Significant Difference post-hoc test, the chi-square test, and
parametric non-paired analysis of variance (ANOVA) with
two-tailed testing at the 5% confidence interval (p= 0.05).
Although all measurements and observations were made in
both eyes, only data from the operated eye were analyzed
and are reported here.
The hospital’s institutional review board approved the
study protocol, which followed the principles set forth in
the Declaration of Helsinki. It was conducted according to
ethical standards for clinical research and surgery and was
approved by the Ethics Committee for Analysis of Research
Projects (CAPPesq) of the Clinical Board of Hospital das
Clı´nicas, University of Sa˜o Paulo (Approval number 388/
11). Drugs were provided by Allergan Laboratories, Inc.
& RESULTS
Sixteen patients enrolled in Group I and 4 patients
enrolled in Group II were withdrawn from the study due
to absence from a scheduled assessment at any point during
the follow-up period. One patient in Group I presented
ocular trauma and required another surgery; this patient
was excluded from the study.
Group I included 47 eyes that received the fixed
combination of gatifloxacin/prednisolone acetate eye drops
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and a placebo eye drop solution. Group II included 61 eyes
that were treated with 0.3% gatifloxacin and 1% predniso-
lone acetate eye drops separately. The treatment groups
were similar regarding patient age, sex, race, and iris color.
Group I comprised 28 female patients (59.6%) and 19 male
patients (40.4%), and Group II comprised 45 female patients
(73.8%) and 16 male patients (26.2%). The average patient
age was 71 years in both groups (Table 1).
Visual acuity improved from a mean of 0.3 (¡0.3)
logMAR on postoperative day 1 to 0.1 (¡0.2) logMAR on
postoperative day 20 in both groups (Figure 1). There was a
gradual reduction in pain scores in both groups, but no
statistically significant differences were observed.
Itching was observed in 11.7% (¡4.06%) of patients in
Group I and 11.12% (¡2.13%) of patients in Group II
throughout the follow-up period; there was no statistically
significant difference between the groups. Burning sensa-
tion was reported by 8.61% (¡6.44%) of patients in Group I
and 8.22% (¡5.17%) of patients in Group II throughout the
follow-up period; the maximum values for burning sensa-
tion were present at the last assessment (p.0.05).
Photophobia was reported by 0-6% of the patients in both
groups (2.15¡1.78 for Group I and 5.77¡1.66 for Group II)
during the assessment period. Group II presented higher
photophobia scores during the follow-up period, but no
statistically significant difference was observed. Foreign
body sensation occurred in 16-32% of the patients in both
groups (mean 21.4¡5.29 for Group I and 25.5¡7.8 for
Group II) throughout the follow-up period (p.0.05).
Conjunctival hyperemia was present in both groups until
postoperative day 7 and gradually decreased over the
evaluation period (Figure 2).
Only one patient from Group II presented a pupillary
membrane in front of the IOL on postoperative day 20 due
to endophthalmitis. None of the patients presented hypop-
yon or IOL pigmentation. Three patients (6%) from Group I
and five patients (8%) from Group II presented opacity of
the posterior capsule, but no statistically significant differ-
ence was observed between the groups.
Central and incisional corneal edema presented similar
results for both groups during the evaluation period, and a
progressive decrease was verified, but there was no
statistically significant difference between the groups.
Regarding anterior chamber cell counting, both groups
presented an average of 21 to 50 cells (score 3) on
postoperative day 1, and a reduction to less than five cells
(score 0) was observed in both groups at the end of the
follow-up period (Figure 3). Flare was similar for both
groups during the study, gradually decreasing over time
(Figure 4).
The maximum intraocular pressure was 12.81 (¡0.06)
mmHg in Group I and 13.67 (¡0.23) mmHg in Group II;
this difference in pressure was statistically significant
(p,0.05) (Figure 5).
Figure 1 - Visual acuity (average, logMAR) in patients treated
with gatifloxacin 0.3% and prednisolone acetate 1% eye drops
combined (Group I) or separately (Group II).
Table 1 - Demographic data (gender and age) for patients treated with gatifloxacin 0.3% and prednisolone acetate 1%
eye drops in combination (Group I) or separately (Group II).
Gender Age
Female Male Average (¡ standard deviation) Min Max
Group I 28 (59.6%) 19 (40.4%) 71 (¡10) 44 88
Group II 45 (73.8%) 16 (26.2%) 71 (¡10) 41 88
Figure 2 - Conjunctival hyperemia score (average and standard
error) in patients treated with gatifloxacin 0.3% and predniso-
lone acetate 1% eye drops in combination (Group I) or separately
(Group II).
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Seven patients (15%) from Group I and eight patients
(13%) from Group II presented increased anterior chamber
cell count, conjunctival hyperemia, and pain score on
postoperative day 20 (five days after medication suspen-
sion), with no statistically significant difference between the
groups.
& DISCUSSION
Data were obtained from patients who underwent
cataract surgery and IOL implantation at a reference
hospital in Sa˜o Paulo, Brazil. Patient demographics were
similar in the study groups.
Gatifloxacin 0.3% is an 8 methoxy-substituted fluoroqui-
nolone agent with greater potency against gram-positive
organisms and certain species of atypical mycobacteria than
earlier generation fluoroquinolones while retaining excel-
lent coverage against Gram-negative bacteria (5,11).
Gatifloxacin 0.3% has also been shown to have excellent
penetration into the aqueous (6,15,16). An important factor
that contributes to the success of antibiotic therapy is the
ability of the molecule to penetrate the target tissues at
concentrations greater than the minimum inhibitory con-
centration (MIC). The concentration of gatifloxacin in the
aqueous humor reaches and exceeds the MIC levels for the
most common ocular pathogens (6), except for fluoroqui-
nolone-resistant S. aureus. (5). This antibiotic exceeded the
known MIC values for most pathogens that cause
endophthalmitis (5).
Coagulase-negative Staphylococci resistance to third- and
fourth-generation fluoroquinolones has been observed in
recent studies. These resistant bacteria emerge rapidly after
exposure to the antibiotic and are maintained by periodic
reexposure (17,18).
The mechanisms of Staphylococcus resistance to fluor-
oquinolones consist of mutations in the gyrA and parC
genes. Fluoroquinolone-resistant S. epidermidis isolated
from clinical samples has emerged rapidly because of the
frequent and repeated use of these antibiotics.
Approximately 10% of the S. epidermidis strains isolated
from ocular infections are resistant to gatifloxacin. The
irrational use of gatifloxacin for the treatment of ocular
infections could increase the prevalence of resistant strains
(18).
The efficacies of the two presentations of the drugs used
in this study were assessed by comparing the two treatment
groups for signs of inflammation, including hyperemia or
edema of the lids or conjunctiva, ocular discharge, structural
changes of the cornea, photophobia, pain, and excessive
tearing. These findings were similar to our clinical observa-
tions of an increased inflammatory response for the first few
days after surgery, which gradually decreased and ended
by the end of the second week.
The main effectiveness criterion was the rate of anterior
chamber cell decrease. A progressive decrease in anterior
chamber cell count after the first postoperative day was
found on slit-lamp examination, suggesting that the
inflammatory reaction was controlled in both groups.
After the eye drop treatments were suspended, 15 patients
Figure 3 - Cell score in the anterior chamber (average and
standard error) in patients treated with gatifloxacin 0.3% and
prednisolone acetate 1% eye drops in combination (Group I) or
separately (Group II).
Figure 4 - Flare score in the anterior chamber (average and
standard error) in patients treated with gatifloxacin 0.3% and
prednisolone acetate 1% eye drops in combination (Group I) or
separately (Group II).
Figure 5 - Intraocular pressure (average and standard error) in
patients treated with gatifloxacin 0.3% and prednisolone
acetate 1% eye drops in combination (Group I) or separately
(Group II). (* p,0.05)
CLINICS 2013;68(6):834-839 Efficacy of gatifloxacin/prednisolone acetate
Cunha PA et al.
837
presented an increase in anterior chamber cell count,
conjunctival hyperemia, pain, and photophobia complaints,
with no statistically significant difference between the
groups. This mild intraocular inflammation resolved after
the reintroduction and tapering of the prednisolone acetate
drops. Therefore, this episode may have been caused by
steroid withdrawal syndrome caused by the abrupt suspen-
sion of the corticosteroid eye drops. Previous studies have
demonstrated that ocular rebound inflammation may
develop secondary to rapid tapering or abrupt discontinua-
tion of topical ocular steroid use and is best prevented with
gradual tapering (19). The mechanisms by which rebounds
in ocular disease may follow steroid withdrawal are still
uncertain (20).
Continuous administration of corticosteroid inhibits the
feedback mechanism involving hypothalamic-pituitary-
adrenal (HPA) functions. Using large doses for a few days
or smaller doses for more than two weeks often leads to a
prolonged decrease in HPA function. Absorption of any
oculary administered corticosteroid through the nasal or
pharyngeal mucosa has the potential to produce adverse
systemic effects. Tapering the drug, generally over four to
six weeks, allows the adrenal glands time to return to their
normal secretion patterns (21).
Prednisolone monotherapy after postoperative day 20,
instead of the combined formula, can be used to promote
inflammation control and avoid corticosteroid withdrawal
syndrome and bacteria resistance.
One of our patients presented with a surgically induced
intraocular infection on postoperative day 20, likely caused
by Propionibacterium acnes. The eye had inflammatory
exacerbations and remissions, with recurrence after treat-
ment. Inflammation resolved after vitrectomy with removal
of the intraocular lens and capsular bag, but an infection
agent could not be isolated from either the aqueous or
vitreous humors or capsule bag cultures.
With regard to the safety parameters of visual acuity,
ocular pain, and intraocular pressure, eyes that received the
fixed combination of gatifloxacin/prednisolone acetate eye
drops were similar to those that used the non-fixed
combination. There was no adverse reaction related to
either drug regimen. Combined and separated gatifloxacin
0.3% and prednisolone acetate 1% were safe and resulted in
improved visual acuity, less pain, and intraocular pressure
within the normal range (22,23). The intraocular pressure
was 1 mmHg lower in Group I than in Group II, but this
difference was not clinically significant.
One advantage of a fixed combination of antibiotic and
anti-inflammatory agents is the lower exposure of the eye to
the toxic effect of preservative agents. Previous in vitro
studies have demonstrated the toxic effect in the corneal
endothelium, reducing cell survival (13). The detergent
properties of BAK (the most common topical ophthalmic
medication preservative) interfere with the integrity of the
external lipid layer of the precorneal tear film, reduce tear
film breakup time, and exacerbate dry eye symptoms. Even
in low concentrations, the extended use of eye drops with
preservatives may cause adverse reactions, whereas highly
concentrated preservatives can cause immediate damage
and irritation to the ocular tissue (12,14).
Other advantages of the fixed combination treatment are
the ease of use and better treatment compliance, with no
administration mistakes and drug washout by concomitant
eye drop application within a short time interval (24-26).
In conclusion, the use of a fixed combination is as
effective as a non-fixed combination but could be more
convenient for the patient, has better treatment compliance,
and increases the likelihood of receiving the proper dosage
(24-31).
Both fixed and non-fixed combinations of gatifloxacin
0.3% and prednisolone acetate 1% are similarly effec-
tive in reducing inflammation and infection prophylaxis
after phacoemulsification surgery and intraocular lens
implantation.
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